At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...

Eosinophilic esophagitis (EoE) is a multifaceted disease marked by diverse clinical features, including variations in age of ...

randomized 2:1 to either LYR-210 (7500µg mometasone furoate) or sham control for 24 weeks.

Each ENLIGHTEN trial enrolled approximately 180 CRS patients who have failed medical management and have not had prior ethmoid sinus surgery, randomized 2:1 to either LYR-210 (7500µg mometasone ...

Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 –WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc.

randomized 2:1 to either LYR-210 (7500µg mometasone furoate) or sham control for 24 weeks. Planned Reverse Stock Split Lyra intends to implement a reverse stock split in order to increase the per ...